STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

WASHINGTON — Advocates mounted a massive push to protect abortion rights at the state level in Tuesday’s election, but ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

The president-elect campaigned on promises to shake up public health institutions, reshape federal health programs, and slash ...

Congress will face big health care issues next year, such as the expiration of enhanced Affordable Care Act subsidies.

Massachusetts voters on Tuesday rejected Question 4, the ballot measure that proposed decriminalizing the use of psychedelic ...

With Donald Trump’s victory in the presidential election, public health experts are anxiously waiting to see whether his ...

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

Donald Trump has been called the winner of the election. As STAT’s Sarah Owermohle writes, Trump’s second term as president ...

What will a second Donald Trump presidency mean for the regulation of medicines in the U.S.? History isn’t likely to repeat ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.